AI News>Press Release
- Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
- Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
- BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc. - BSGM
- HELIOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Heliogen, Inc. - HLGN
- SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc. - SGN
- TASK Investigation: Kessler Topaz Meltzer & Check, LLP Encourages TaskUs, Inc. (NASDAQ:TASK) Investors to Contact the Firm
- INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Broadmark Realty Capital Inc., Ready Capital Corporation, Others and Announces Opportunity for Investors with Substantial Losses to Lead Lawsuit – BRMK; RC
- Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
- Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
- URGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
- BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
- Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
- Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
- Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
- Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
- In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
- BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
- Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
- Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
- ICHOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Ichor Holdings, Ltd.
- Mason Capital Management apoyará la lista de consejeros recomendada por Grifols en la próxima asamblea general ordinaria
- Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
- New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
- KBRA Affirms and Withdraws Rating for Fortegra Financial Corp, Assigns Ratings for The Fortegra Group, Inc., and Fortegra Specialty Insurance Company, and Affirms Ratings for Debt and Fortegra's Key Insurance Subsidiaries
- ¿Todos listos? Right Now de Grindr ya es global
- KBRA Comments on Amendment to Sunnova's Loan Guarantee Agreement with DOE
- LGI Homes Debuts New CompleteHome™ Plus Section at Star Valley in Tucson, AZ
- Unity Wealth Partners and Tidal Financial Group Announce the Closure of the Unity Wealth Partners Dynamic Capital Appreciation & Options ETF (Nasdaq: DCAP)
- Oak Woods Acquisition Corporation Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
- Digi Power X Establishes US$100 Million at-the-Market Equity Program to Accelerate Growth
- INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Tempus AI Inc. (NASDAQ: TEM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
- DoorDash Announces Closing of Upsized $2.75 Billion Offering of 0% Convertible Senior Notes
- INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of EchoStar Corporation (NASDAQ: SATS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
- Grupo Aeroportuario del Pacifico Announces Drawdown of Ps. 3,375 Million Credit Facility
- Celularity Receives Nasdaq Notice Regarding Form 10-Q
- CoStar Group and Happening Technology End Dispute Amicably
- Stantec Announces Private Offering of $425 Million Senior Unsecured Notes
- Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
- Upstart CFO to Participate in Fireside Chat at the Morgan Stanley US Financials Conference
- Pembina Pipeline Corporation Announces Redemption of Series 19 Preferred Shares
- Corning Energy Announces CEO Appointment
- Goldman Sachs Asset Management Announces Final Liquidating Distribution of $0.291 Per Share for Goldman Sachs MLP and Energy Renaissance Fund
- Karman Space & Defense to Present at the William Blair 45th Annual Growth Stock Conference
- State Street to Speak at the Morgan Stanley U.S. Financials Conference
- Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
- Real Announces $150 Million Share Repurchase Authorization
- ContextLogic Inc. to Commence Trading on the OTC Markets and Delist from Nasdaq
- Pelican Acquisition Corporation Announces Closing of Full Underwriters' Over-Allotment Option in connection with its Initial Public Offering